Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin for prevention of contrast-induced kidney damage in chronic kidney disease
TCTR20210123004Phase 3Completed
- Sponsor
- Cardiac Electrophysiology Research and Training Center
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of melatonin in contrast-induced nephropathy (CIN), chronic kidney disease (CKD), sponsored by Cardiac Electrophysiology Research and Training Center. Started Jan 2021; status: completed.
02
Drugs
melatonin
03
Conditions
contrast-induced nephropathy (CIN)chronic kidney disease (CKD)
Beyond the preview
Go deeper on TCTR20210123004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20210123004.